References of "CAVALIER, Etienne"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailEstablishment of reference values for 6 six steroids in serum
LE GOFF, Caroline ULiege; Fabregat Cabello, Neus ULiege; Huyghebaert, Loreen ULiege et al

in Clinical Chemistry and Laboratory Medicine (2017, June)

Detailed reference viewed: 43 (3 ULiège)
Full Text
Peer Reviewed
See detailReference interval determination for serum and urine aldosterone for healthy Belgian population
LE GOFF, Caroline ULiege; Fabregat Cabello, Neus ULiege; Huyghebaert, Loreen ULiege et al

in Clinical Chemistry & Laboratory Medicine (2017, June)

Detailed reference viewed: 30 (3 ULiège)
Full Text
Peer Reviewed
See detailComparison of cardiac biomarker fluctuation in runners of marathons, semi-marathons and untrained runners
LE GOFF, Caroline ULiege; VRANKEN, Laura ULiege; van Nueten, Jan et al

in Clinical Chemistry & Laboratory Medicine (2017, June)

Detailed reference viewed: 23 (2 ULiège)
Full Text
Peer Reviewed
See detailImpact of an ultra-trail of 330 km on plasma levels
LE GOFF, Caroline ULiege; Kaux, Jean-François ULiege; Gergelé, Laurent et al

in Clinical Chemistry and laboratory medicine (2017, June)

Detailed reference viewed: 19 (1 ULiège)
Full Text
Peer Reviewed
See detailHypercalcemie par mutation inactivatrice du CYP24A1. Etude d'un cas et revue de la litterature.
Seidowsky, Alexandre; Villain, Cedric; Vilaine, Eve et al

in Néphrologie & Thérapeutique (2017)

We present the case of a family whose members have high levels of serum calcium (hypercalcaemia) by loss of function of the enzyme vitamin D 24-hydroxylase due to bi-allelic mutations in the CYP24A1 gene ... [more ▼]

We present the case of a family whose members have high levels of serum calcium (hypercalcaemia) by loss of function of the enzyme vitamin D 24-hydroxylase due to bi-allelic mutations in the CYP24A1 gene: c.443 T>C (p.Leu148Pro) and c.1187 G>A (p.Arg396Gln). 24-VITD hydroxylase is a key player in regulating the circulating calcitriol, its tissue concentration and its biological effects. Transmission is recessive. The estimated prevalence of stones in the affected subjects is estimated between 10 and 15%. The loss of peripheral catabolism of vitamin D metabolites in patients with an inactivating mutation of CYP24A1 is responsible for persistent high levels of 1,25-dihydroxyvitamin D especially after sun exposure and a charge of native vitamin D. Although there are currently no recommendations (French review) on this subject, this disease should be suspected in association with recurrent calcium stones with nephrocalcinosis, and a calcitriol-dependent hypercalcaemia with adapted low parathyroid hormone levels. Resistance to corticosteroid therapy distinguishes it from other calcitriol-dependent hypercalcemia. A ratio of 25-hydroxyvitamin D/24.25 hydroxyvitamin D>50, is in favor of hypercalcemia with vitamin D deficiency 24-hydroxylase. Genetic analysis of CYP24A1 should be performed at the second step. The current therapeutic management includes the restriction native vitamin D supplementation and the limitation of sun exposure. Biological monitoring will be based on serum calcium control and modulation of parathyroid hormone concentrations. [less ▲]

Detailed reference viewed: 14 (2 ULiège)
Full Text
Peer Reviewed
See detailPerspective and priorities for improvement of parathyroid hormone (PTH) measurement - A view from the IFCC Working Group for PTH.
Sturgeon, Catharine M.; Sprague, Stuart; Almond, Alison et al

in Clinica Chimica Acta (2017), 467

Parathyroid hormone (PTH) measurement in serum or plasma is a necessary tool for the exploration of calcium/phosphate disorders, and is widely used as a surrogate marker to assess skeletal and mineral ... [more ▼]

Parathyroid hormone (PTH) measurement in serum or plasma is a necessary tool for the exploration of calcium/phosphate disorders, and is widely used as a surrogate marker to assess skeletal and mineral disorders associated with chronic kidney disease (CKD), referred to as CKD-bone mineral disorders (CKD-MBD). CKD currently affects >10% of the adult population in the United States and represents a major health issue worldwide. Disturbances in mineral metabolism and fractures in CKD patients are associated with increased morbidity and mortality. Appropriate identification and management of CKD-MBD is therefore critical to improving clinical outcome. Recent increases in understanding of the complex pathophysiology of CKD, which involves calcium, phosphate and magnesium balance, and is also influenced by vitamin D status and fibroblast growth factor (FGF)-23 production, should facilitate such improvement. Development of evidence-based recommendations about how best to use PTH is limited by considerable method-related variation in results, of up to 5-fold, as well as by lack of clarity about which PTH metabolites these methods recognise. This makes it difficult to compare PTH results from different studies and to develop common reference intervals and/or decision levels for treatment. The implications of these method-related differences for current clinical practice are reviewed here. Work being undertaken by the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) to improve the comparability of PTH measurements worldwide is also described. [less ▲]

Detailed reference viewed: 25 (1 ULiège)
Full Text
Peer Reviewed
See detailBiomarkers of osteoarthritis : practical considerations.
CAVALIER, Etienne ULiege; Reginster, Jean-Yves ULiege

in Osteoporosis International (2017, March), 28 Suppl 1

Detailed reference viewed: 32 (2 ULiège)
Full Text
Peer Reviewed
See detailAnalytical and clinical validation of the new Abbot Architect 25(OH)D assay: fit for purpose?
Cavalier, Etienne ULiege; LUKAS, Pierre ULiege; BEKAERT, Anne-Catherine ULiege et al

in Clinical Chemistry & Laboratory Medicine (2017), 55(3), 378-384

BACKGROUND: We provide a clinical and analytical evaluation of the reformulated version of the Abbott Architect 25-hydroxyvitamin D assay. We compared this assay with three commercial automated ... [more ▼]

BACKGROUND: We provide a clinical and analytical evaluation of the reformulated version of the Abbott Architect 25-hydroxyvitamin D assay. We compared this assay with three commercial automated immunoassays and against a VDSP-traceable liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) in six different populations. We also supplemented 40 healthy volunteers with either 600,000 IU of vitamin D2 or 100,000 of vitamin D3 to evaluate the performance of the immunoassays vs. the LC-MS/MS. METHODS: Precision and limit of quantification were assessed, 25(OH)D2 and C3-epimer recovery were calculated. Two hundred and forty samples obtained in healthy Caucasians and Africans, osteoporotic, hemodialyzed and intensive care patients and 3rd trimester pregnant women were analyzed by all methods. Correlation was studied using Passing-Bablok and Bland-Altman analysis. Concordance correlation coefficient (CCC) was calculated to evaluate agreement between immunoassays and LC-MS/MS. We verified if patients were homogeneously classified with the immunoassays when they took vitamin D2 or vitamin D3 after 1, 7 and 28 days. RESULTS: We observed excellent analytical features and showed a very good correlation to the LC-MS/MS results in the overall population. Compared to the other immunoassays, concordance of the new Abbott assay with the LC-MS/MS was at least similar, and often better in diseased populations. Althought the cross-reactivity with 25(OH)D2 was not of 100%, there was no significant difference in the classifications of the patients, either supplemented with D2 or D3 or after 7 or 28 days. CONCLUSIONS: This modified version of the Abbott Architect assay is clearly improved compared to the previous one and presents a better agreement with the LC-MS/MS. [less ▲]

Detailed reference viewed: 47 (17 ULiège)
Full Text
Peer Reviewed
See detailHow the reference values for serum parathyroid hormone concentration are (or should be) established?
Souberbielle, J.-C.; Brazier, F.; Piketty, M.-L. et al

in Journal of Endocrinological Investigation (2017), 40(3), 241-256

Well-validated reference values are necessary for a correct interpretation of a serum PTH concentration. Establishing PTH reference values needs recruiting a large reference population. Exclusion criteria ... [more ▼]

Well-validated reference values are necessary for a correct interpretation of a serum PTH concentration. Establishing PTH reference values needs recruiting a large reference population. Exclusion criteria for this population can be defined as any situation possibly inducing an increase or a decrease in PTH concentration. As recommended in the recent guidelines on the diagnosis and management of asymptomatic primary hyperparathyroidism, PTH reference values should be established in vitamin D-replete subjects with a normal renal function with possible stratification according to various factors such as age, gender, menopausal status, body mass index, and race. A consensus about analytical/pre-analytical aspects of PTH measurement is also needed with special emphasis on the nature of the sample (plasma or serum), the time and the fasting/non-fasting status of the blood sample. Our opinion is that blood sample for PTH measurement should be obtained in the morning after an overnight fast. Furthermore, despite longer stability of the PTH molecule in EDTA plasma, we prefer serum as it allows to measure calcium, a prerequisite for a correct interpretation of a PTH concentration, on the same sample. Once a consensus is reached, we believe an important international multicentre work should be performed to recruit a very extensive reference population of apparently healthy vitamin D-replete subjects with a normal renal function in order to establish the PTH normative data. Due to the huge inter-method variability in PTH measurement, a sufficient quantity of blood sample should be obtained to allow measurement with as many PTH kits as possible. [less ▲]

Detailed reference viewed: 39 (11 ULiège)
Full Text
Peer Reviewed
See detailImpact of an ultra-marathon of 330km on plasma levels of cardiac biomarkers
Le Goff, Caroline ULiege; Kaux, Jean-François ULiege; Gergelé, Laurent et al

in British Journal of Sports Medicine (2017, February), 51(4), 347

Detailed reference viewed: 23 (2 ULiège)
Full Text
Peer Reviewed
See detailThe added value of plasma or urinary NGAL concentrations in clinical practice
Gregoire, Emilien ULiege; Claisse, Guillaume; GUIOT, Julien ULiege et al

Poster (2017, January 13)

Detailed reference viewed: 39 (4 ULiège)
Full Text
Peer Reviewed
See detailEtude rétrospective du bilan thyroïdien: définition de valeurs de référence pédiatriques
LADANG, Aurélie ULiege; VRANKEN, Laura ULiege; LUYCKX, Françoise ULiege et al

in Revue Médicale de Liège (2017)

Defining reference range is an essential tool for diagnostic. Age and sexe influences on thyroid hormone levels have been already discussed. In this study, we are defining a new pediatric reference range ... [more ▼]

Defining reference range is an essential tool for diagnostic. Age and sexe influences on thyroid hormone levels have been already discussed. In this study, we are defining a new pediatric reference range for TSH, FT3 and FT4 for Cobas C6000 analyzer. To do so, we have taken in account 0 to 18 year old outclinic patients. During the first year of life, thyroid hormone levels change dramatically before getting stabilized around 3 years old. We also compared our results to those obtained in a Canadian large-scale prospective study (the CALIPER initiative). [less ▲]

Detailed reference viewed: 82 (5 ULiège)
Full Text
Peer Reviewed
See detailAssessment of vitamin D status - a changing landscape.
Herrmann, Markus; Farrell, Christopher-John L.; Pusceddu, Irene et al

in Clinical Chemistry & Laboratory Medicine (2017)

In recent years it has been shown that vitamin D deficiency is associated with an increased incidence as well as the progression of a broad range of diseases including osteoporosis, rickets ... [more ▼]

In recent years it has been shown that vitamin D deficiency is associated with an increased incidence as well as the progression of a broad range of diseases including osteoporosis, rickets, cardiovascular disease, autoimmune disease, multiple sclerosis and cancer. Consequently, requests for the assessment of vitamin D status have increased dramatically. Despite significant progress in the analysis of vitamin D metabolites and an expansion of our pathophysiological knowledge of vitamin D, the assessment of vitamin D status remains a challenging and partially unresolved issue. Current guidelines from scientific bodies recommend the measurement of 25-hydroxy vitamin D (25-OHD) in blood as the preferred test. However, growing evidence indicates significant limitations of this test, including analytical aspects and interpretation of results. In addition, the relationships between 25-OHD and various clinical indices, such as bone mineral density and fracture risk, are rather weak and not consistent across races. Recent studies have systematically investigated new markers of vitamin D status including the vitamin D metabolite ratio (VMR) (ratio between 25-OHD and 24,25-dihydroxy vitamin D), bioavailable 25-OHD [25-OHD not bound to vitamin D binding protein (DBP)], and free 25-OHD [circulating 25-OHD bound to neither DBP nor albumin (ALB)]. These parameters may potentially change how we will assess vitamin D status in the future. Although these new biomarkers have expanded our knowledge about vitamin D metabolism, a range of unresolved issues regarding their measurement and the interpretation of results prevent their use in daily practice. It can be expected that some of these issues will be overcome in the near future so that they may be considered for routine use (at least in specialized centers). In addition, genetic studies have revealed several polymorphisms in key proteins of vitamin D metabolism that affect the circulating concentrations of vitamin D metabolites. The affected proteins include DBP, 7-dehydrocholesterol synthase and the vitamin D receptor (VDR). Here we aim to review existing knowledge regarding the biochemistry, physiology and measurement of vitamin D. We will also provide an overview of current and emerging biomarkers for the assessment of vitamin D status, with particular attention methodological aspects and their usefulness in clinical practice. [less ▲]

Detailed reference viewed: 26 (7 ULiège)